Galderma Group N (GALD SW) stock market data APIs
CHF147.3045
0.3(0.2%)
as of February 6, 2026
Try our APIs with
free plan!
Galderma Group N Financial Data Overview
Price chart is built with
Anychart
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Prev. Close
147.3045
Open
147.6045
High
148.3059
Low
144.6479
52 wk Range
72.5788-170.1
Market Cap
34 827 M
P/E Ratio
119.2683
Shares Outstanding
235 M
Revenue
4 690 M
EPS
0.82
Dividends (Yield)
0.0011
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galderma Group N (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galderma Group N data using free add-ons & libraries
Get Galderma Group N Fundamental Data
Galderma Group N Fundamental data includes:
- Net Revenue: 4 690 M
- EBITDA: 988 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-24
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galderma Group N News
New
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-sever...
Galderma Group (SWX:GALD) Valuation Check After Recent Share Price Weakness And R&D Driven Growth Hopes
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. What recent moves in Galderma Group say about investor sent...
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three s...
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Wake Up to Restylane ‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
